ClearPoint Neuro Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? ClearPoint Neuro Inc trades at $15.69 (market cap $478.63M), while Consumer Staples Select Sector SPDR Fund trades at $83.28. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | XLP | |
|---|---|---|
Market Cap | $478.63M | — |
Sector | Health | — |
52-Week High | $29.60 | $90.00 |
52-Week Low | $8.66 | $75.61 |
Enterprise Value | $506.63M | — |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.58, up 0.55% with a bullish technical signal from moving averages. The ETF holds 36 consumer staples stocks and offers a 2.6% dividend yield. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid market uncertainty, with retail sales hitting 12-month highs supporting the sector.
XLP presents a defensive investment opportunity with stable dividend income and low volatility characteristics. The fund's concentrated portfolio of essential consumer goods companies provides resilience during market downturns. Key risks include sector rotation away from defensive stocks and potential margin pressure from inflation. Current technical strength and positive analyst sentiment support near-term upside potential.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →